text:
famous hoosiers (130)
debs, eugene v. (eugene victor), 1855-1926 (30)
political prisoners (20)
image/tiff 300 dpi epson gt-20000 epson scan (81)
image/gif epson perfection v700 epson scan 3.83; 1350 dpi grayscale (6)
image/tiff (6)
28 x 21.5 cm. (5)
image/tiff epson perfection v700 epson scan 3.83; 650 dpi 8-bit grayscale (4)
image/tiff 375 dpi epson gt-20000 adobe photoshop elements 2.0 (3)
image/tiff epson perfection v700 epson scan 3.83; 1350; 8-bit grayscale (3)
adobe photoshop elements 9; epson gt-20000 (2)
debs, theodore, 1864-1945 (64)
robins, lucy (5)
lewis, fay (4)
stone, irving, 1903-1989 (4)
hillquit, morris, 1869-1933 (3)
thurman, ray (3)
All fields: go
Landis, J. T. 1921-11-05
Writing;
Letter to Eugene V. Debs, 11/5/1921. Says that he has heard that the government leaders in Washington D. C. are seriously considering letting Eugene V. Debs go free. Writes that it is clear that the activities on behalf of the political prisoners...
Laitinen, Gertrude 1921-05-31
Letter to Eugene V. Debs, 5/31/1921. Expresses the hope that Eugene V. Debs will soon be free. Says that she has been teasingly asking her mother to go to Russia. Includes a note from Eugene V. Debs to Theodore Debs saying that "this rising...
Le Prade, Ruth 1920-03-01
Letter to Eugene V. Debs, 3/1/1920. Writes that when Eugene V. Debs went to prison the "light of the world seemed to go out." Says that Eugene V. Debs' imprisonment made it difficult for her to get through school. Tells Eugene V. Debs that she...
Lewis, Fay n.d
Letter from Theodore Debs, n.d. Tells Lewis that Katherine Debs has passed on. Mentions that he did not mourn her death because of the way that she betrayed Eugene V. Debs' final wishes, which was that his estate was to go to the Socialist...
Letter from Theodore Debs, n.d. Tells Lewis that Katherine Debs has passed on. Mentions that he did not mourn her death because of the way that she betrayed Eugene V. Debs' final wishes, which was that his estate was to go to the Socialist...
Lewis, Fay 1926-11-05
Letter from Theodore Debs, 11/5/1926. Says that Eugene V. Debs wrote her a letter a year ago that said something to the effect of, "I have given all my life to the cause and when I pass on what little I have left will go to the Socialist Party." ...
Debs, Katherine Metzel 1926-11-09
Wills; Debs, Eugene V. (Eugene Victor), 1855-1926 -- Death and burial; Socialist Party of the United States of America; Law & legal affairs;
Letter from Theodore Debs, 11/09/1926. Says that he was surprised to find out that the will Eugene V. Debs told him about was not probated. Writes that in the will Eugene V. Debs told him about "practically everything belonging to him at the time...
Debs, Eugene V. 1910-12-24
Warren, Fred D., 1872 or 3-1959; Political prisoners; Christmas; Salutations; Appeal to Reason;
Letter to Theodore Debs on APPEAL TO REASON letterhead, 12/24/1910. Tells Theodore that he is sorry he will not be home for Christmas. Mentions that Fred Warren told him "with tears in his eyes" the he needed him at this time. Says he sees...
Tin day article, Glenn Indiana
War work; Propaganda; Caricatures;
Circular about tin day. It asks people to bring their tin cans, clean and dry to the school for pickup to go for the war effort. It has a caricature of a Japanese soldier at the top and holly leaves on the bottom.
Debs, Jean Daniel 1895-10-06
Vacations; Debs family; Debs, Eugene V. (Eugene Victor), 1855-1926; Writing; Socialism -- United States -- Newspapers; Debs, Katherine Metzel; Debs, Theodore, 1864-1945;
Letter to Emily Debs Mailloux, 10/06/1895. Writes that he has received her letter informing him of her departure for Europe. Mentions that he has her sent a copy of a letter which Eugene V. Debs wrote for a Chicago, Illinois newspaper. Says that...
Coldwell, Joseph M. 1943-10-20
United States Penitentiary, Atlanta, Georgia; Debs, Eugene V. (Eugene Victor), 1855-1926; Stone, Irving, 1903-1989; Biography;
Letter from Theodoe Debs, 10/20/1943. Says that he talked to many old-timers before allowing Irving Stone access to Eugene V. Debs's materials. Tells Coldwell that he cannot go back on his word now and not let Stone use Eugene V. Debs's...
Darrow, Clarence 1920-01-14
United States Penitentiary, Atlanta, Georgia; Debs, Eugene V. (Eugene Victor), 1855-1926 -- Trials, litigation, etc.; Political prisoners;
Letter to Eugene V. Debs on New Willard, Washington D. C. letterhead, 1/14/20. Tells Eugene V. Debs that he did not go to the Attorney General with Debs's case. Thinks that Eugene V. Debs and the other political prisoners will be released when...
Civil War: George Gegner letter to Lizzie Wayman, November 23, 1864
United States -- History -- Civil War, 1861-1865; Letters; Camps; Marching; Soldiers; United States. Army. Indiana Infantry Regiment, 130th (1863-1865);
A letter from George Gegner to his future wife, Lizzie Wayman, dated November 23, 1864. Gegner was stationed in Johnsonville, Tennessee at the time he wrote the letter. In the letter, George tells Lizzie how he and his friend John built a shelter...
Civil War: George Gegner letter to Lizzie Wayman, December 27, 1864
A letter from George Gegner to his future wife, Lizze Wayman, dated December 27, 1864. Gegner was stationed near Columbia, Tennessee at the time he wrote the letter. George tells Lizzie that his Regiment moved their camp to a nicer place near...
Civil War: George Gegner letter to Lizzie Wayman, September 25, 1864.
United States -- History -- Civil War, 1861-1865; Letters; Camps; Marching; Soldiers; Railroad mail service; Sabbaths; United States. Army. Indiana Infantry Regiment, 130th (1863-1865);
A letter from George Gegner to his future wife, Lizzie Wayman, dated September 25, 1864. Gegner was stationed in Decatur, Georgia at the time he wrote the letter. In the letter, George tells Lizzie that it had rained the week beforebut as he writes...
Thompson, W.H. 1913-06-17
United Mine Workers of America; Press, Socialist;
Letter to Eugene V. Debs on SOCIALIST LABOR STAR letterhead, 06/17/1913. Writes that he was not able to get his story before the Senate as he hoped because he, nor any of the other comrades persecuted by Henry Hatfield, were put on the stand. Says...
White, John P. 1915-04-16
United Mine Workers of America;
Letter to Eugene V. Debs on United Mine Workers of America letterhead, 04/16/1915. Says that he wants to know from what source Eugene V. Debs got the information for his article in the NATIONAL RIP-SAW titled "Ten Convicted Labor Leaders." Informs...
Supernatural encounters---ufos
Unidentified flying objects; Light; Supernatural;
This is Mandy M. Staub's typewritten account of a UFO that appeared in the sky.
This is Troy D. McQueen's typewritten account of a UFO that appeared in the sky.
Traubel, Horace 1901-07-02
Traubel, Horace, 1858-1919; Books;
Letter from Stephen Marion Reynolds on Davis, Reynolds and Davis, Attorneys letterhead, 07/02/1901. Writes that he would like 3 copies of Traubel's book. Says that he wished that he could share Traubel's trials and tribulations. Assures Traubel...


text:
Home › Entertainment › TV › Yellowstone › 'Yellowstone' Star Gator Shows You How to Make Turkey the Dutton Way
'Yellowstone' Star Gator Shows You How to Make Turkey the Dutton Way
by Jon D. B. November 19, 2021
written by Jon D. B. November 19, 2021 11:34 am
(Photo Credit: Yellowstone Gallery, Paramount Network Press Center, Viacom)
"Be advised: Watching Gator cook on the set of Yellowstone WILL make you hungry." Paramount's smash hit is once again putting the spotlight on Gabriel "Gator" Guilbeau, chef-extraordinaire both on and off screen.
If you love Yellowstone (which, let's face it, is why you're here) then you love Gator. Gabriel Guilbeau plays chef for Paramount's cowboys in front of and behind the camera. Audiences at home know him as the Dutton family cook, Gator. But he's also feeding the entire cast and crew behind-the-scenes nearly 24-7.
"My name's Gator, and I'm in charge of craft services. Moral support. Shoulders to cry on. Snackies," the chef begins for Working the Yellowstone: 'Gator-ing'. "I'm feeding cowboys on the camera and off the camera."
There's no shortage of love for what the Louisiana native does, either. "Gator is like a culinary Picasso," offers co-star Jen Landon (Teeter). "Nobody cooks like Gator."
"He is from Louisiana, and he brings all of that love into his cooking," smile's Monica Dutton's Kelsey Asbille.
"He's such a good guy, and such a character," adds cowboy Ethan Lee (Ethan on Yellowstone). "I love him on and off set. If Gator's cookin', I'm going."
"We have taken to calling him 'Gatoring' in leu of 'catering,'" reveals Ryan's Ian Bohen. "It is now a man with a truck that is open for business breakfast, lunch, and dinner. Snacks in-between. Crawfish etouffe," you name it, the actor continues.
The Man, The Myth, The Legend: Gator
As for Gator himself, "My dad has done craft service for 27 years," he cites. "He used to do big movies out in LA. I have a long history of cooks in the family, being that we're real Cajuns."
As much as any man alive, Gator's blood runs thick with the glorious grease of Cajun cooking. Guilbeau's grandmother was a renowned chef in Southern Louisiana. "So it just comes natural for us to feed people. It's just what we do. I don't know any other way."
Gator began cooking professionally as soon as he got out of high school. The job? "Working on some super small, horrible, ice-cold movie in Baton Rouge, Louisiana," he laughs. "I froze my butt off and worked my butt off, and said 'I'm going to go get all my stuff!' And I never turned back after that."
His big introduction to audiences was the now infamous "grilled octopus" scene, a fan favorite to this day. This was Gator's "first time on camera, ever," too. "Baptism by fire, man."
Gator's Star of the Show? 'Yellowstone' Turkey
And it only got better from there. One of Gator's all-time-favorite tools is his enormous smoker, which he uses to make Yellowstone turkey. For the show's feature, he's got "fifteen twenty-five-pound turkeys in there," and they look glorious. For how to get these birds cookin' the same way yourself, check out Yellowstone's full feature below.
https://www.youtube.com/watch?v=iyOOtKRlHjg
Video can't be loaded because JavaScript is disabled: Working the Yellowstone: 'Gator-ing' | Paramount Network (https://www.youtube.com/watch?v=iyOOtKRlHjg)
Be advised: Watching Gator cook on the set of Yellowstone WILL make you hungry. In this behind-the-scenes look, brought to you by ZipRecruiter, Gabriel "Gator" Guilbeau discusses his delicious role on the show. Yellowstone airs Sundays at 8/7c on Paramount Network.

redpajama_set_name: RedPajamaCommonCrawl


Distance from Chesapeake, OH to Bear, DE is 487Miles or 783 Km. You can get this distance about 7 hours 22 mins.
A car with an average MPG will needs 22.55 gallons of gas to get the route between these points.
The estimated cost of gas to get between Chesapeake, OH and Bear, DE is $51.19.
During the route, an average car will release 441.8 pounds of CO2 to the atmosphere. Your carbon footprint is 0.91 pounds of CO2 per mile.


text:
TransLaboratory
Cooking up translations for world
Blade Online
Translator: humbletroll
Editor: HDGGXIN
As usual point out the mistakes. Enjoy!
Here's something my Editor wants to say:
I saw LOGAN … It was good. The female wolverine is very vicious.
The Bone Spider moved to attack us at a terrifying speed using all of its eight legs. I evaded the attack by moving sideways. I cut the rear of the spider using 〈〈Void Slash〉〉 and a transparent slash cut the spider's peculiar buttocks1(rear) off. The HP of the spider did not decrease by much. Even if given at my level and the fact that I used 〈〈Void Slash〉〉, there wasn't much damage.Though the Bone spider had a comparatively strong defense, but it looks like my 〈〈Void Slash〉〉 wasn't strong enough for boss level monsters.
The Bone Spider stood up on its four legs and looked back.
The Bone Spider jumped on us just as it is to crush us. Using 〈〈Step〉〉 we jumped backwards and evaded it. As for the attack, when it fell down, a great shock wave was released in the surroundings. Naturally, Bone Spider received some damage itself when it fell down so it could not attack soon hence I waited for the shock wave to disappear. As the Bone Spider wouldn't be able to move for a while, so it's our the best chance to attack it. We approach it in a dash and attacked it at same time using respective skills.
"〈〈Force Slash〉〉"
"〈〈Tri Stab〉〉"
"〈〈Heavy Swing〉〉"
My quadruple, Rin's Tri stab and Ryuu's new skill – "Heavy Swing" simultaneously hammered onto the Bone Spider's face. We were able to reduce its HP by 30% at a stretch. It was written on the bulletin board that the Bone Spider would not be able to move once it uses its skill. So, we retreated as soon as the attack was over. A few seconds later, the Bone Spider straightened up and vigorously attacked with its sickle-like chelicera at the spot where we were a while go. Chelicera were the 2 fang-like things you see on a spider's mouth. If someone got caught in that huge scissor-mouth then there would no escape. It's important to gather information after all.
*Shaaaa* The moment the Bone Spider shrieked while shaking his chelicera, about 10 skeletons came out from under the ground. Indeed. It's difficult to fight both Bone spiders and skeletons at the same time. It would have been difficult for Ryuu and Rin alone, but since I was here so there wasn't any problem. I quickly eliminate the emerging skeletons using 〈〈Void Slash〉〉.
"It feels like cheating already."
Ryuu who saw it smiled wryly. It was no such thing to that degree. If it were the lead group then it would be easy for them.
The Bone Spider started to move again. It was a Charge attack. We split to left and right to avoid the attack.
The Bone Spider did not stop after doing this once. It vigorously turned back and charged again. Rin was its target. I became stiff due to astonishment. Shit! I instructed them beforehand to be careful because charging attack would not be over after one time.
Ryuu ran at the same time I shouted at her to avoid it. He tried to intercept the Bone Spider in the middle of its charge by pushing away Rin with all his strength and placed himself in front of it while holding his axe. Too rash. At your level, it's impossible to face the charge of such thing from the front.
(TL: This reminded of Ryosuke trying to stop shinigami's GTR with his FC but the ending is not same here. For those who don't understand, it's Initial D reference)
I clicked my tongue and dashed with everything I had. I am pretty confident of the speed that I had trained in "Bloody Forest". However, I could not make it in time. Ryuu used 〈〈Heavy Swing〉〉 and swung his axe downwards onto the face of Bone Spider. As his axe struck the head of Bone Spider, at the same time Ryuu got blown away by its charge. After flying in the air not knowing for how many meters, finally after a few seconds he dropped and tumbled on the ground. Ryuu's HP was decreasing at an alarming rate. Even though he won't die thanks to 〈〈Vitality〉〉, but the sensation of pain in this world was almost same as the real world. Ryuu dropped down dead tired. He may not be able to move for a while, Shit! isn't this same as the previous2 boss fight!?
I rushed to Ryuu and picked him up. It seems that he still hasn't lost his consciousness. He somehow managed to hold on.
"Ryuu quickly drink the potion!"
"Yes…… Sorry……"
Ryuu who forced a smile while having a pained expression took out a potion from item box and slowly swallowed. HP was restored into the safe zone. It's safe for the time being. The pain would not disappear instantly, but he should be able to recover himself in few minutes.
Rin came running towards us while looking ghastly pale and having tears in her eyes.
"I'm sorry, I'm sorry, I'm sorry……. Forgive me Onii-chan….."
She thought that Ryuu was killed by that single slow. After knowing that he was alive, she felt relieved but then began shedding tears….. It was impossible to fight like this anymore. It can't be helped. Looks like I have to tell them to fall back and defeat the boss myself huh?
"Both of you, fall back. I will defeat that thing."
Just as I was going towards the Bone Spider. When I looked back, he(Ryuu) already stood up and his facial expression seemed to be quite comfortable too.
"We will also fight. There would be no meaning if we leave everything to Akatsuki-san only."
"Let us fight!"
Rin and Ryuu said so with a serious expression. I don't have any reason to not let them fight.
"Understood. Act as discussed during the briefing."
When I said so, both of them broke into a joyful expression for an instance and returned to serious look again.
From here on, our attack was excellent. While avoiding the charge and pressing attacks of Bone spider, whenever we got an opportunity, we would go all out with our attacks. Since I knocked down the immediately created skeletons so there weren't any problems. The Bone Spider crawled up the wall and the came right 3 above us and rocked his body shudderingly.
Then a large number of bones fell off from its body. His body was getting smaller, however, it's not a problem.
We avoid the falling bones. If I am not mistaken, the bones would form into huge Skeleton which was bigger than normal ones. The bone stuck together and transformed into three big Skeletons. Two of them were cleared up by 〈〈Force Slash〉〉 and a remaining skeleton was defeated by Rin and Ryuu using a combo of 〈〈Tri Stab〉〉 and 〈〈Force Swing〉〉.
When the Skeletons were finished, the Bone Spider which became smaller than usual suddenly fell down. It was written on the Bulletin Board that some members of Lead Group became the prey of this sudden fall. Of course, we avoided it since we knew about this. The Bone Spiders HP reduced by 10% due to rebound by the floor. The scattered fragments of the Skeletons fly around.
"Let's end this!!"
Together, we gave one last blow to the immovable Bone Spider. With that, the Bone Spider's HP became zero. The Bone Spider's trembled while giving out a scream and its bone fell around itself. In the end, they were only ordinary bones and model has disappeared. The bones which were scattered became grains and disappeared.
TL Notes:
1 Buttocks here means the bulging back part of spider which is the abdomen of a spider and is called Opisthosoma. I guess author wrote like this to make it easy to understand or he was lazy to google it. See this for more info.
2 See Chapter 20 for information.
3 The monster was clung to the roof of the pit. Like this –
Previous Chapter TOC Next Chapter
7 thoughts on "Chapter 32"
GM_Rusaku
(='.'=) Thanks!!
("")_("") Nepu!!!
sfcipher
Thank you for the chapter.
Thank you for the chapter! Is vitality the ability that prevents one shot kills?
humbletroll
There is no full explanation about it till now tbh. But it is a parameter of player which has a value. It can be said simply said to be stamina.
Nijima Melodiam
Actually, I think it was earlier said that there was a somewhat rare skill that some armors made from boss materials have called Vitality (the same as the stat). Also, it made your HP 1 if you were to be one shot (and if I remember correctly, that is).
Dark Jackel
Quick, loot the body– wait, it already disappeared… 😋
Pingback: Blade Online - Chapter 32 - Zenith Novels
Chapter 35: Posted
Chapter 37: 20 %
Three chapters a week.
Please support us by clicking the adfly link for viewing the chapters. We need funds to upgrade website
Follow TransLaboratory on WordPress.com
humbletroll on Chapter 27
autokredit vergleich on Chapter 27
Nijima Melodiam on Chapter 32
Dash on Chapter 27


The Marine Aquarium Conference of North America (MACNA) is the oldest marine aquarium conference in North America.
MACNA is managed by the Marine Aquarium Societies of North America (MASNA), supporting the goals and programs of the MASNA charter.
MACNA is a combination of several events. It is an educational symposium where people can attend lectures from industry leaders, conservationists, authors, and scientists. It is also a trade show where hobbyists can buy the hottest new corals and see new cutting edge equipment. Attendees can also give their feedback to manufacturers so they can continue to bring us the innovations we are looking for. And lastly it is a social event. Many speakers, vendors, and hobbyists come to socialize with each other. It gives people an opportunity to put faces with names they might see on a message board or email.
The 30 Years of MACNA!
Tom McCarthy of the Cleveland Saltwater Enthusiasts' Association (C-SEA) made a phone call to Scott Dyer of the Marine Aquarium Society of Toronto (MAST). The idea presented was to organize a joint event featuring a prominent speaker to be attended by both societies' memberships. Scott replied to Tom that he had been thinking along the same lines and it was from this simple start that the idea of a weekend conference was born. MAST agreed to host the first Marine Aquarium Conference of North America (MACNA) and C-SEA agreed to reciprocate the following year.
Helmut Debelius (Red Sea Fish and Invertebrates).
The Conference was held in the main lecture hall of the Royal Ontario Museum and featured several new products on display for the benefit of attendees and participants. Saturday night featured cocktails and a banquet (establishing the MAC NA tradition of carrying on well into the night hours). The MACNA I Committee, in alphabetical order, consisted of: Ken Burrows, Sheila Byers, Charles Delbeek, Roger Driessen, Scott Dyer, Bob Harris, Russell Jardine, Paula and Goran Jovanevic, Bev and Chris Knight, Ian Shapiro, Ron Tuur, and many more who helped on the day of the Conference.
MACNA II was planned and organized by C-SEA's Dave Egloff, Ron and Iris Garsteck, Tim Hemsoth, Joe Keyon, Dominic Madonia, Tom McCarthy, Kent Seward, and Roger Seward.
Frank Murru (Sea World and Maintenance of Public Aquaria).
Neville Coleman (Brisbane, Australia) was also the featured speaker at the Saturday night buffet held on the grounds of Sea World. Toronto and Cleveland had made a great contribution to the aquarium hobby by taking on the organization and planning of these first two conferences. Excitement ran high at each event – so high that the idea of an annual conference kept surfacing. If there were to be a third MACNA, who would host it? Fortunately, in attendance at MACNA II, were members of Windows to the Sea Marine Aquarium Society (NJ). They returned from Ohio and presented the idea of hosting a conference to their club (Windows). In October of 1990, Windows agreed to "take the plunge" and commit itself to hosting MACNA Ill.
MACNA III was held on April 20-21, 1991 at the Radisson Hotel, Newark International Airport, New Jersey. Windows organized seven committees: Publicity (Bob Denton), Program (Bob Denton), Fund Raising (Allan Starace), Banquet (May Markoff), Audio-Visual (Jerry Riedler), Journal – i.e. Advertising, Layout and Design (Mehul Sheth), and Finance (Jack Snyder).
The Saturday night banquet was a sit-down affair with a fixed menu. Following the banquet, aquarists adjourned to another room where Helmut Debelius delivered a breathtaking slide presentation entitled "Discovering a New Angelfish" . Attendance at the third conference ran well over 300 – MACNA had become a known and awaited event in the aquarium world. Florida had been approached through Beth Hayden to possibly host MACNA IV. Florida Marine Aquarium Society (FMAS) members, like their New Jersey counterparts, were in attendance at MACNA III, and returned home to present the possibility to their Club of hosting a Conference in Miami.
MACNA IV was supposed to have been held September 19-20, 1992 at the Sonesta Beach Hotel on Key Biscayne. In August of 1992, Hurricane Andrew devastated south Florida leaving residents without phones, power, water, food, housing and gas. The Sonesta Beach Hotel was unusable. Once phone communications were restored, the FMAS Board was able to meet to decide whether to try and continue with MACNA. It was decided that if an alternate hotel with adequate space and facilities could be found, MACNA IV would take place as scheduled. FMAS was successful in relocating the Conference to Dania, Florida (north of Miami) and a phone committee was set up to call every registrant to confirm the Conference was on and explain the shift in locale. Hotel, banquet and ancillary service negotiations, completed months ago, were speedily renegotiated. A Friday night "get-acquainted" reception and "mini-program" was provided for attendees and speakers.
Panel Discussion: The Future of the Marine Aquarium Hobby in North America: Is There One?
Charles Delbeek (Stingers, Suckers, Munchers and Maulers: An Introduction to Reef Aquarium Parasites and Pests).
Two repeating workshops, offered twice each day, were given by Godfrey Waugh and Jill Hambrook-Broz (The A-B-C's of Marine Fish Nutrition) and Martin Moe (How to Raise 100 Clownfish and Still Keep a Job and Your Spouse).
Approximately 400 attendees came to Dania from the U.S., Puerto Rico, Canada, Europe and throughout the U.S. Co-Chairs for MACNA IV were Beth Hayden and Richie Strassberg. Committee members included: Michele Arena, Cindy Bickford, Danny Garcia, Debbie Garcia, Nancy Lempicki, Bruce Moreland, Michael Robert, Roseanne Strassberg and Tom Cavanaugh. Toronto (MAST) had already indicated its willingness to host MACNA V – for the first time, it was possible to announce at the close of MACNA IV, that not only would a MACNA V take place, but when and where it would be held and what club would host it.
On Saturday evening attendees were bussed to the Ontario Palace for a gourmet dinner and spectacular presentation of slides entitled "Wild Aquarium I" presented by Rudi Kuiter in the Cinesphere's IMAX theater. The two upcoming conferences were already scheduled: MACNA VI would return to Cleveland/C-SEA and MACNA VII would be hosted by the Louisville Marine Aquarium Society (LMAS) in Louisville, Kentucky in 1995.
Gerald Heslinga (Micronesian Mariculture Demonstration Center – Mariculture Efforts).
A cash bar preceded the Saturday night banquet after which Richard Pyle presented a slide show of rare and exotic deep-dwelling marines. During the course of the Conference, Stuart Keefer gave a brief, unscheduled presentation on his "Eco-Labeling Project".
MACNA VI drew the largest attendance to date with well over 400 aquarists, professional and amateur. With Conference planning well coordinated in advance, Louisville was able to distribute brochures for its upcoming MACNA VII at the Cleveland Conference.
Vendor participation increased as well at Louisville. There were over twenty two well known vendors displaying. The Saturday night Banquet was well presented and Dr. Gerald Allen thrilled us with a nine position multimedia production shown on a back projected screen. The First MASNA "Outstanding Hobbyist" award was presented to Martin Moe.
• Melev's Reef: What is MACNA? Why should you attend?
• MACNA 1998: Aquarium Design's photos.
• MACNA 2007: Melev's photos.
• MACNA 2007: Walt's MACNA 2007 Banquet Video.
• MACNA 2008: Victor90's ReefCentral photos.
• MACNA 2012: Melev's photos.
• MACNA 2014: Matt Rogers' 3Reef photos.


Distance from Los Angeles International Airport to Licenciado Gustavo Díaz Ordaz International Airport is 1218 miles / 1960 kilometers / 1058 nautical miles.
Estimated flight time from Los Angeles International Airport (LAX) to Licenciado Gustavo Díaz Ordaz International Airport (PVR) is 2 hours 48 minutes.
The time difference between Los Angeles and Puerto Vallarta is 2 hours. Puerto Vallarta is 2 hours ahead of Los Angeles.
Flight map from Los Angeles to Puerto Vallarta.
Los Angeles (LAX) → Puerto Vallarta (PVR).


The Main-Transit Fire Department has been serving the town of Amherst, New York in Emergency Medical, Fire and Motor Vehicle Rescue Services. The Main-Transit Fire Department is a 100% volunteer organization that serves a district of approximately 5.2 square miles. We also work with many other neighboring departments when a F.A.S.T Team or Mutual Aid is needed.
Our membership consists of over 85 Active Members, a Ladies Auxiliary, an Exempt Association, and an Explorers Post with 25 members. All active members are required to have passed New York State certified courses in firefighting, and maintain First Aid certifications. Many members are Certified First Responders, along with some Emergency Medical Technicians and Paramedics.
Located at Main and Ferndale, Main-Transit Station No.1 is situated on approximately 18 acres land, which is also the site for the fire departments training facility, pavilion, softball diamond and Banquet hall. Main-Transit Station No.1 houses most of our apparatus including two class 'A' engines, a heavy rescue, ladder truck, class III ambulance and two utility trucks. Station No.1 also has a diesel-powered generator, which is capable of powering the entire facility for several days before refueling.


text:
Tremonti Drop Full Throttle New Song 'Now and Forever,' Announce Livestream Concert
Chad Childers Published: September 21, 2021
Gina Wetzler, Getty Images
It's now just a matter of days until Tremonti's full studio album, Marching in Time, is available everywhere, but the guitarist-singer is giving fans the final taste of fresh music before it arrives. Arriving today (Sept. 21) is a new lyric video for the song "Now and Forever" off Tremonti's fifth studio album.
Set against a darkened backdrop with visually compelling black and white shapes shifting throughout the clip, the lyric video offers a backdrop fitting for the song. The track definitely falls in the heavier range with pulsing low end that can most certainly be felt throughout the body and should be quite the sensation in the live setting.
The song is featured on Tremonti's Marching in Time album that arrives this Friday (Sept. 24). Pre-orders for the set are available at this location.
And speaking of release day, Tremonti also have something else special in store. The band will be playing their first ever livestream concert, broadcast through NoCapShows, this Friday (Sept. 24) at 9PM ET/6PM PT. The show will also be available for the entire following week after the premiere.
Tremonti promise a setlist comprised of songs from the new album as well as fan favorites from the previous four releases. So be sure to check out the show and get your tickets here. And you can also look for Tremonti and his band on tour this fall.
Tremonti, "Now and Forever"
2021's Best Rock Songs (So Far)
Loudwire's picks for the best rock songs of 2021 so far.
Source: Tremonti Drop Full Throttle New Song 'Now and Forever,' Announce Livestream Concert
Filed Under: mark tremonti


To reduce the development of drug-resistant bacteria and maintain the effectiveness of Invanz® and other antibacterial drugs, Invanz should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Invanz is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2)].
Invanz is indicated for the treatment of acute pelvic infections including postpartum endomyometritis, septic abortion and post surgical gynecological infections due to Streptococcus agalactiae, Escherichia coli, Bacteroides fragilis, Porphyromonas asaccharolytica, Peptostreptococcus species, or Prevotella bivia.
DO NOT MIX OR CO-INFUSE Invanz WITH OTHER MEDICATIONS. DO NOT USE DILUENTS CONTAINING DEXTROSE (α-D-GLUCOSE).
Invanz may be administered by intravenous infusion for up to 14 days or intramuscular injection for up to 7 days. When administered intravenously, Invanz should be infused over a period of 30 minutes. Intramuscular administration of Invanz may be used as an alternative to intravenous administration in the treatment of those infections for which intramuscular therapy is appropriate.
The dose of Invanz in patients 13 years of age and older is 1 gram (g) given once a day [see Clinical Pharmacology (12.3)].
The dose of Invanz in patients 3 months to 12 years of age is 15 mg/kg twice daily (not to exceed 1 g/day).
Table 1 presents treatment guidelines for Invanz.
Invanz has not been studied in diabetic foot infections with concomitant osteomyelitis [see Clinical Studies (14.1)].
duration includes a possible switch to an appropriate oral therapy, after at least 3 days of parenteral therapy, once clinical improvement has been demonstrated.
Table 2 presents prophylaxis guidelines for Invanz.
When adult patients on hemodialysis are given the recommended daily dose of 500 mg of Invanz within 6 hours prior to hemodialysis, a supplementary dose of 150 mg is recommended following the hemodialysis session. If Invanz is given at least 6 hours prior to hemodialysis, no supplementary dose is needed. There are no data in patients undergoing peritoneal dialysis or hemofiltration. There are no data in pediatric patients on hemodialysis.
When only the serum creatinine is available, the following formula1 may be used to estimate creatinine clearance. The serum creatinine should represent a steady state of renal function.
Invanz MUST BE RECONSTITUTED AND THEN DILUTED PRIOR TO ADMINISTRATION.
Reconstitute the contents of a 1 g vial of Invanz with 10 mL of one of the following: Water for Injection, 0.9% Sodium Chloride Injection or Bacteriostatic Water for Injection, using a syringe equipped with a 21-gauge or smaller diameter needle. NOTE: Use with a needleless IV system is not recommended.
Shake well to dissolve and immediately transfer contents of the reconstituted vial to 50 mL of 0.9% Sodium Chloride Injection.
Complete the infusion within 6 hours of reconstitution.
Invanz MUST BE RECONSTITUTED PRIOR TO ADMINISTRATION.
Reconstitute the contents of a 1 g vial of Invanz with 3.2 mL of 1.0% lidocaine HCl injection2 (without epinephrine). Shake vial thoroughly to form solution.
Immediately withdraw the contents of the vial and administer by deep intramuscular injection into a large muscle mass (such as the gluteal muscles or lateral part of the thigh).
The reconstituted IM solution should be used within 1 hour after preparation. NOTE: THE RECONSTITUTED SOLUTION SHOULD NOT BE ADMINISTERED INTRAVENOUSLY.
Shake well to dissolve and immediately withdraw a volume equal to 15 mg/kg of body weight (not to exceed 1 g/day) and dilute in 0.9% Sodium Chloride Injection to a final concentration of 20 mg/mL or less.
Reconstitute the contents of a 1 g vial of Invanz with 3.2 mL of 1.0% lidocaine HCl injection (without epinephrine). Shake vial thoroughly to form solution.
Immediately withdraw a volume equal to 15 mg/kg of body weight (not to exceed 1 g/day) and administer by deep intramuscular injection into a large muscle mass (such as the gluteal muscles or lateral part of the thigh).
Refer to the prescribing information for lidocaine HCl.
When prepared with the diluent, Invanz (Ertapenem for Injection) maintains satisfactory potency for 6 hours at room temperature (25°C) or for 24 hours under refrigeration (5°C) and used within 4 hours after removal from refrigeration. Solutions of Invanz should not be frozen.
Before administering, see accompanying package circular for Invanz (Ertapenem for Injection).
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to use, whenever solution and container permit. Solutions of Invanz range from colorless to pale yellow. Variations of color within this range do not affect the potency of the product.
Invanz is a sterile lyophilized powder in a vial containing 1.046 g ertapenem sodium equivalent to 1 g ertapenem for intravenous infusion or for intramuscular injection.
Invanz is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams.
Due to the use of lidocaine HCl as a diluent, Invanz administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type.
CDAD has been reported with use of nearly all antibacterial agents, including ertapenem, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of Clostridium difficile.
Clostridium difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of Clostridium difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against Clostridium difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of Clostridium difficile, and surgical evaluation should be instituted as clinically indicated.
As with other antibiotics, prolonged use of Invanz may result in overgrowth of non-susceptible organisms. Repeated evaluation of the patient's condition is essential. If superinfection occurs during therapy, appropriate measures should be taken.
Prescribing Invanz in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
The following are described in greater detail in the Warnings and Precautions section.
Clinical trials enrolled 1954 patients treated with Invanz; in some of the clinical trials, parenteral therapy was followed by a switch to an appropriate oral antimicrobial [see Clinical Studies (14)]. Most adverse experiences reported in these clinical trials were described as mild to moderate in severity. Invanz was discontinued due to adverse experiences in 4.7% of patients. Table 3 shows the incidence of adverse experiences reported in ≥2.0% of patients in these trials. The most common drug-related adverse experiences in patients treated with Invanz, including those who were switched to therapy with an oral antimicrobial, were diarrhea (5.5%), infused vein complication (3.7%), nausea (3.1%), headache (2.2%), and vaginitis in females (2.1%).
In patients treated for complicated intra-abdominal infections, death occurred in 4.7% (15/316) of patients receiving Invanz and 2.6% (8/307) of patients receiving comparator drug. These deaths occurred in patients with significant co-morbidity and/or severe baseline infections. Deaths were considered unrelated to study drugs by investigators.
In clinical trials, seizure was reported during study therapy plus 14-day follow-up period in 0.5% of patients treated with Invanz, 0.3% of patients treated with piperacillin/tazobactam and 0% of patients treated with ceftriaxone [see Warnings and Precautions (5.2)].
Urogenital System: renal impairment, oliguria/anuria, vaginal pruritus, hematuria, urinary retention, bladder dysfunction, vaginal candidiasis, vulvovaginitis.
In a clinical trial for the treatment of diabetic foot infections in which 289 adult diabetic patients were treated with Invanz, the adverse experience profile was generally similar to that seen in previous clinical trials.
In a clinical trial in adults for the prophylaxis of surgical site infection following elective colorectal surgery in which 476 patients received a 1 g dose of Invanz 1 hour prior to surgery and were then followed for safety 14 days post surgery, the overall adverse experience profile was generally comparable to that observed for Invanz in previous clinical trials. Table 4 shows the incidence of adverse experiences other than those previously described above for Invanz that were reported regardless of causality in ≥2.0% of patients in this trial.
Respiratory, Thoracic and Mediastinal Disorders: crackles lung, lung infiltration, pulmonary congestion, pulmonary embolism, wheezing.
Clinical trials enrolled 384 patients treated with Invanz; in some of the clinical trials, parenteral therapy was followed by a switch to an appropriate oral antimicrobial [see Clinical Studies (14)]. The overall adverse experience profile in pediatric patients is comparable to that in adult patients. Table 5 shows the incidence of adverse experiences reported in ≥2.0% of pediatric patients in clinical trials. The most common drug-related adverse experiences in pediatric patients treated with Invanz, including those who were switched to therapy with an oral antimicrobial, were diarrhea (6.5%), infusion site pain (5.5%), infusion site erythema (2.6%), vomiting (2.1%).
Includes Phase IIb Complicated skin and skin structure infections, Community acquired pneumonia and Complicated urinary tract infections trials in which patients 3 months to 12 years of age received Invanz 15 mg/kg IV twice daily up to a maximum of 1 g or ceftriaxone 50 mg/kg/day IV in two divided doses up to a maximum of 2 g, and patients 13 to 17 years of age received Invanz 1 g IV daily or ceftriaxone 50 mg/kg/day IV in a single daily dose.
Includes Phase IIb Acute pelvic infections and Complicated intra-abdominal infections trials in which patients 3 months to 12 years of age received Invanz 15 mg/kg IV twice daily up to a maximum of 1 g and patients 13 to 17 years of age received Invanz 1 g IV daily or ticarcillin/clavulanate 50 mg/kg for patients <60 kg or ticarcillin/clavulanate 3.0 g for patients >60 kg, 4 or 6 times a day.
The following additional adverse reactions have been identified during the post-approval use of Invanz. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Laboratory adverse experiences that were reported during therapy in ≥2.0% of adult patients treated with Invanz in clinical trials are presented in Table 6. Drug-related laboratory adverse experiences that were reported during therapy in ≥2.0% of adult patients treated with Invanz, including those who were switched to therapy with an oral antimicrobial, in clinical trials were ALT increased (6.0%), AST increased (5.2%), serum alkaline phosphatase increased (3.4%), and platelet count increased (2.8%). Invanz was discontinued due to laboratory adverse experiences in 0.3% of patients.
Additional laboratory adverse experiences that were reported during therapy in >0.1% of patients treated with Invanz in clinical trials include: increases in serum creatinine, serum glucose, BUN, total, direct and indirect serum bilirubin, serum sodium and potassium, PT and PTT; decreases in serum potassium, serum albumin, WBC, platelet count, and segmented neutrophils.
In a clinical trial for the treatment of diabetic foot infections in which 289 adult diabetic patients were treated with Invanz, the laboratory adverse experience profile was generally similar to that seen in previous clinical trials.
In a clinical trial in adults for the prophylaxis of surgical site infection following elective colorectal surgery in which 476 patients received a 1 g dose of Invanz 1 hour prior to surgery and were then followed for safety 14 days post surgery, the overall laboratory adverse experience profile was generally comparable to that observed for Invanz in previous clinical trials.
Laboratory adverse experiences that were reported during therapy in ≥2.0% of pediatric patients treated with Invanz in clinical trials are presented in Table 7. Drug-related laboratory adverse experiences that were reported during therapy in ≥2.0% of pediatric patients treated with Invanz, including those who were switched to therapy with an oral antimicrobial, in clinical trials were neutrophil count decreased (3.0%), ALT increased (2.2%), and AST increased (2.1%).
Additional laboratory adverse experiences that were reported during therapy in >0.5% of patients treated with Invanz in clinical trials include: alkaline phosphatase increased, eosinophil count increased, platelet count increased, white blood cell count decreased and urine protein present.
Available data from a small number of postmarketing cases with Invanz use in pregnancy are insufficient to inform any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies after intravenous administration of ertapenem during the period of organogenesis, there was no evidence of developmental malformations in rats at systemic exposures (AUC) up to approximately 1.2 times the human exposure at the maximum recommended human dose (MRHD) and in mice at doses up to approximately 3 times the MRHD based on body surface area comparison. In pregnant rats administered ertapenem during organogenesis through lactation, fetal toxicity, developmental delays, and impaired reproduction did not occur in first generation offspring at systemic exposures (AUC) approximately 1.2 times the human exposure at the MRHD (see Data).
In pregnant rats, intravenous administration of ertapenem dosages of up to 700 mg/kg/day (approximately 1.2 times the MRHD based on AUC) during the period of organogenesis (gestation days [GD] 6-20) revealed no maternal or embryofetal effects.
Pregnant mice intravenously administered ertapenem dosages of up to 700 mg/kg/day (approximately 3 times the MRHD based on body surface area comparison) during the period of organogenesis (GD 6-15) showed slight decreases in average fetal weight and an associated decrease in the average number of ossified sacrocaudal vertebrae. There were no maternal effects at any dosage.
In a pre-postnatal study in rats, ertapenem administered to pregnant rats at dosages up to 700 mg/kg/day (approximately 1.2 times the MRHD based on AUC) during organogenesis through lactation, (GD 6 until Lactation Day (LD) 20) did not result in fetal toxicity, developmental delays, or impaired reproduction in first generation offspring, and fetal deaths and malformations were not increased in second generation offspring.
Ertapenem is present in human milk (see Data). There are no data on the effects on the breastfed infant or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Invanz and any potential adverse effects on the breastfed infant from Invanz or from the underlying maternal condition.
The concentration of ertapenem in breast milk from 5 lactating women with pelvic infections (5 to 14 days postpartum) measured at random time points daily for 5 consecutive days following the last 1 g dose of intravenous therapy (3 to 10 days of therapy) showed low levels. The concentration of ertapenem in breast milk within 24 hours of the last dose of therapy in all 5 women ranged from (<0.13 (lower limit of quantitation) to 0.38 mcg/ml), although peak concentrations were not assessed. By day 5 after discontinuation of therapy, the level of ertapenem was undetectable in the breast milk of 4 women and below the lower limit of quantitation (<0.13 mcg/mL) in 1 woman. The concentration of ertapenem in transitional milk observed in this study may not reflect the concentration of ertapenem in mature milk.
Safety and effectiveness of Invanz in pediatric patients 3 months to 17 years of age are supported by evidence from adequate and well-controlled trials in adults, pharmacokinetic data in pediatric patients, and additional data from comparator-controlled trials in pediatric patients 3 months to 17 years of age [see Indications and Usage (1.1), (1.2), (1.3), (1.4) and (1.5) and Clinical Studies (14.2)].
Invanz is not recommended in infants under 3 months of age as no data are available.
Invanz is not recommended in the treatment of meningitis in the pediatric population due to lack of sufficient CSF penetration.
Of the 1,835 patients in Phase 2b/3 trials treated with Invanz, approximately 26 percent were 65 and over, while approximately 12 percent were 75 and over. No overall differences in safety or effectiveness were observed between these patients and younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Dosage and Administration (2.2)].
No specific information is available on the treatment of overdosage with Invanz. Intentional overdosing of Invanz is unlikely. Intravenous administration of Invanz at a dose of 2 g over 30 min or 3 g over 1-2h in healthy adult volunteers resulted in an increased incidence of nausea. In clinical trials in adults, inadvertent administration of three 1 g doses of Invanz in a 24 hour period resulted in diarrhea and transient dizziness in one patient. In pediatric clinical trials, a single intravenous dose of 40 mg/kg up to a maximum of 2 g did not result in toxicity.
In the event of an overdose, Invanz should be discontinued and general supportive treatment given until renal elimination takes place.
Invanz can be removed by hemodialysis; the plasma clearance of the total fraction of ertapenem was increased 30% in subjects with end-stage renal disease when hemodialysis (4 hour session) was performed immediately following administration. However, no information is available on the use of hemodialysis to treat overdosage.
Invanz (Ertapenem for Injection) is a sterile, synthetic, parenteral, 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics.
Ertapenem sodium is a white to off-white hygroscopic, weakly crystalline powder. It is soluble in water and 0.9% sodium chloride solution, practically insoluble in ethanol, and insoluble in isopropyl acetate and tetrahydrofuran.
Invanz is supplied as sterile lyophilized powder for intravenous infusion after reconstitution with appropriate diluent [see Dosage and Administration (2.7)] and transfer to 50 mL 0.9% Sodium Chloride Injection or for intramuscular injection following reconstitution with 1% lidocaine hydrochloride. Each vial contains 1.046 grams ertapenem sodium, equivalent to 1 gram ertapenem. The sodium content is approximately 137 mg (approximately 6.0 mEq).
Each vial of Invanz contains the following inactive ingredients: 175 mg sodium bicarbonate and sodium hydroxide to adjust pH to 7.5.
Average plasma concentrations (mcg/mL) of ertapenem following a single 30-minute infusion of a 1 g intravenous (IV) dose and administration of a single 1 g intramuscular (IM) dose in healthy young adults are presented in Table 8.
The area under the plasma concentration-time curve (AUC) of ertapenem in adults increased less-than dose-proportional based on total ertapenem concentrations over the 0.5 to 2 g dose range, whereas the AUC increased greater-than dose-proportional based on unbound ertapenem concentrations. Ertapenem exhibits non-linear pharmacokinetics due to concentration-dependent plasma protein binding at the proposed therapeutic dose [see Clinical Pharmacology (12.3)]. There is no accumulation of ertapenem following multiple IV or IM 1 g daily doses in healthy adults.
Average plasma concentrations (mcg/mL) of ertapenem in pediatric patients are presented in Table 9.
Ertapenem, reconstituted with 1% lidocaine HCl injection, USP (in saline without epinephrine), is almost completely absorbed following intramuscular (IM) administration at the recommended dose of 1 g. The mean bioavailability is approximately 90%. Following 1 g daily IM administration, mean peak plasma concentrations (Cmax) are achieved in approximately 2.3 hours (Tmax).
Ertapenem is highly bound to human plasma proteins, primarily albumin. In healthy young adults, the protein binding of ertapenem decreases as plasma concentrations increase, from approximately 95% bound at an approximate plasma concentration of <100 micrograms (mcg)/mL to approximately 85% bound at an approximate plasma concentration of 300 mcg/mL.
The apparent volume of distribution at steady state (Vss) of ertapenem in adults is approximately 0.12 liter/kg, approximately 0.2 liter/kg in pediatric patients 3 months to 12 years of age and approximately 0.16 liter/kg in pediatric patients 13 to 17 years of age.
The concentrations of ertapenem achieved in suction-induced skin blister fluid at each sampling point on the third day of 1 g once daily IV doses are presented in Table 10. The ratio of AUC0-24 in skin blister fluid/AUC0-24 in plasma is 0.61.
In healthy young adults, after infusion of 1 g IV radiolabeled ertapenem, the plasma radioactivity consists predominantly (94%) of ertapenem. The major metabolite of ertapenem is the inactive ring-opened derivative formed by hydrolysis of the beta-lactam ring.
Ertapenem is eliminated primarily by the kidneys. The mean plasma half-life in healthy young adults is approximately 4 hours and the plasma clearance is approximately 1.8 L/hour. The mean plasma half-life in pediatric patients 13 to 17 years of age is approximately 4 hours and approximately 2.5 hours in pediatric patients 3 months to 12 years of age.
Following the administration of 1 g IV radiolabeled ertapenem to healthy young adults, approximately 80% is recovered in urine and 10% in feces. Of the 80% recovered in urine, approximately 38% is excreted as unchanged drug and approximately 37% as the ring-opened metabolite.
In healthy young adults given a 1 g IV dose, the mean percentage of the administered dose excreted in urine was 17.4% during 0-2 hours postdose, 5.4% during 4-6 hours postdose, and 2.4% during 12-24 hours postdose.
Total and unbound fractions of ertapenem pharmacokinetics were investigated in 26 adult subjects (31 to 80 years of age) with varying degrees of renal impairment. Following a single 1 g IV dose of ertapenem, the unbound AUC increased 1.5-fold and 2.3-fold in subjects with mild renal impairment (CLCR 60-90 mL/min/1.73 m2) and moderate renal impairment (CLCR 31-59 mL/min/1.73 m2), respectively, compared with healthy young subjects (25 to 45 years of age). No dosage adjustment is necessary in patients with CLCR ≥31 mL/min/1.73 m2. The unbound AUC increased 4.4-fold and 7.6-fold in subjects with advanced renal impairment (CLCR 5-30 mL/min/1.73 m2) and end-stage renal disease (CLCR <10 mL/min/1.73 m2), respectively, compared with healthy young subjects. The effects of renal impairment on AUC of total drug were of smaller magnitude. The recommended dose of ertapenem in adult patients with CLCR ≤30 mL/min/1.73 m2 is 0.5 grams every 24 hours. Following a single 1 g IV dose given immediately prior to a 4 hour hemodialysis session in 5 adult patients with end-stage renal disease, approximately 30% of the dose was recovered in the dialysate. Dose adjustments are recommended for patients with severe renal impairment and end-stage renal disease [see Dosage and Administration (2.4)]. There are no data in pediatric patients with renal impairment.
The pharmacokinetics of ertapenem in patients with hepatic impairment have not been established. However, ertapenem does not appear to undergo hepatic metabolism based on in vitro studies and approximately 10% of an administered dose is recovered in the feces [see Clinical Pharmacology (12.3) and Dosage and Administration (2.6)].
The effect of gender on the pharmacokinetics of ertapenem was evaluated in healthy male (n=8) and healthy female (n=8) subjects. The differences observed could be attributed to body size when body weight was taken into consideration. No dose adjustment is recommended based on gender.
The impact of age on the pharmacokinetics of ertapenem was evaluated in healthy male (n=7) and healthy female (n=7) subjects ≥65 years of age. The total and unbound AUC increased 37% and 67%, respectively, in elderly adults relative to young adults. These changes were attributed to age-related changes in creatinine clearance. No dosage adjustment is necessary for elderly patients with normal (for their age) renal function.
Plasma concentrations of ertapenem are comparable in pediatric patients 13 to 17 years of age and adults following a 1 g once daily IV dose.
Following the 20 mg/kg dose (up to a maximum dose of 1 g), the pharmacokinetic parameter values in patients 13 to 17 years of age (N=6) were generally comparable to those in healthy young adults.
Plasma concentrations at the midpoint of the dosing interval following a single 15 mg/kg IV dose of ertapenem in patients 3 months to 12 years of age are comparable to plasma concentrations at the midpoint of the dosing interval following a 1 g once daily IV dose in adults [see Clinical Pharmacology (12.3)]. The plasma clearance (mL/min/kg) of ertapenem in patients 3 months to 12 years of age is approximately 2-fold higher as compared to that in adults. At the 15 mg/kg dose, the AUC value (doubled to model a twice daily dosing regimen, i.e., 30 mg/kg/day exposure) in patients 3 months to 12 years of age was comparable to the AUC value in young healthy adults receiving a 1 g IV dose of ertapenem.
When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem. Based on total ertapenem concentrations, probenecid increased the AUC of ertapenem by 25%, and reduced the plasma and renal clearance of ertapenem by 20% and 35%, respectively. The half-life of ertapenem was increased from 4.0 to 4.8 hours.
In vitro studies in human liver microsomes indicate that ertapenem does not inhibit metabolism mediated by any of the following cytochrome p450 (CYP) isoforms: 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4.
In vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of digoxin or vinblastine and that ertapenem is not a substrate for P-glycoprotein-mediated transport.
Ertapenem has in vitro activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichia coli, it has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference for PBPs 2 and 3.
Ertapenem is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases. Ertapenem is hydrolyzed by metallo-beta-lactamases.
For specific information regarding susceptibility testing methods, interpretive criteria, and associated test methods and quality control standards recognized by FDA for ertapenem, please see: https://www.fda.gov/STIC.
No long-term studies in animals have been performed to evaluate the carcinogenic potential of ertapenem.
Ertapenem was not genotoxic in in vitro or in vivo assays, including: an alkaline elution/rat hepatocyte assay, a chromosomal aberration assay in Chinese hamster ovary cells, a TK6 human lymphoblastoid cell mutagenesis assay and a mouse micronucleus assay.
In rats, intravenous dosages up to 700 mg/kg/day (approximately 1.2 times the human exposure at the recommended human dose of 1 g based on plasma AUC) did not impair fertility.
In repeat-dose studies in rats, treatment-related neutropenia occurred at every dose-level tested, including the lowest dose of 2 mg/kg (approximately 2% of the human dose on a body surface area basis).
Studies in rabbits and Rhesus monkeys were inconclusive with regard to the effect on neutrophil counts.
Ertapenem was evaluated in adults for the treatment of complicated intra-abdominal infections in a randomized, double-blind, non-inferiority clinical trial. This trial compared ertapenem (1 g intravenously once a day) with piperacillin/tazobactam (3.375 g intravenously every 6 hours) for 5 to 14 days and enrolled 665 patients with localized complicated appendicitis, and any other complicated intra-abdominal infection including colonic, small intestinal, and biliary infections and generalized peritonitis. The combined clinical and microbiologic success rates in the microbiologically evaluable population at 4 to 6 weeks posttherapy (test-of-cure) were 83.6% (163/195) for ertapenem and 80.4% (152/189) for piperacillin/tazobactam.
Ertapenem was evaluated in adults for the treatment of complicated skin and skin structure infections in a randomized, double-blind, non-inferiority clinical trial. This trial compared ertapenem (1 g intravenously once a day) with piperacillin/tazobactam (3.375 g intravenously every 6 hours) for 7 to 14 days and enrolled 540 patients including patients with deep soft tissue abscess, posttraumatic wound infection and cellulitis with purulent drainage. The clinical success rates at 10 to 21 days posttherapy (test-of-cure) were 83.9% (141/168) for ertapenem and 85.3% (145/170) for piperacillin/tazobactam.
Ertapenem was evaluated in adults for the treatment of diabetic foot infections without concomitant osteomyelitis in a multicenter, randomized, double-blind, non-inferiority clinical trial. This trial compared ertapenem (1 g intravenously once a day) with piperacillin/tazobactam (3.375 g intravenously every 6 hours). Test-of-cure was defined as clinical response between treatment groups in the clinically evaluable population at the 10-day posttherapy follow-up visit. The trial included 295 patients randomized to ertapenem and 291 patients to piperacillin/tazobactam. Both regimens allowed the option to switch to oral amoxicillin/clavulanate for a total of 5 to 28 days of treatment (parenteral and oral). All patients were eligible to receive appropriate adjunctive treatment methods, such as debridement, as is typically required in the treatment of diabetic foot infections, and most patients received these treatments. Patients with suspected osteomyelitis could be enrolled if all the infected bone was removed within 2 days of initiation of study therapy, and preferably within the prestudy period. Investigators had the option to add open-label vancomycin if enterococci or methicillin-resistant Staphylococcus aureus (MRSA) were among the pathogens isolated or if patients had a history of MRSA infection and additional therapy was indicated in the opinion of the investigator. Two hundred and four (204) patients randomized to ertapenem and 202 patients randomized to piperacillin/tazobactam were clinically evaluable. The clinical success rates at 10 days posttherapy were 75.0% (153/204) for ertapenem and 70.8% (143/202) for piperacillin/tazobactam.
Ertapenem was evaluated in adults for the treatment of community acquired pneumonia in two randomized, double-blind, non-inferiority clinical trials. Both trials compared ertapenem (1 g parenterally once a day) with ceftriaxone (1 g parenterally once a day) and enrolled a total of 866 patients. Both regimens allowed the option to switch to oral amoxicillin/clavulanate for a total of 10 to 14 days of treatment (parenteral and oral). In the first trial the primary efficacy parameter was the clinical success rate in the clinically evaluable population and success rates were 92.3% (168/182) for ertapenem and 91.0% (183/201) for ceftriaxone at 7 to 14 days posttherapy (test-of-cure). In the second trial the primary efficacy parameter was the clinical success rate in the microbiologically evaluable population and success rates were 91% (91/100) for ertapenem and 91.8% (45/49) for ceftriaxone at 7 to 14 days posttherapy (test-of-cure).
Ertapenem was evaluated in adults for the treatment of complicated urinary tract infections including pyelonephritis in two randomized, double-blind, non-inferiority clinical trials. Both trials compared ertapenem (1 g parenterally once a day) with ceftriaxone (1 g parenterally once a day) and enrolled a total of 850 patients. Both regimens allowed the option to switch to oral ciprofloxacin (500 mg twice daily) for a total of 10 to 14 days of treatment (parenteral and oral). The microbiological success rates (combined trials) at 5 to 9 days posttherapy (test-of-cure) were 89.5% (229/256) for ertapenem and 91.1% (204/224) for ceftriaxone.
Ertapenem was evaluated in adults for the treatment of acute pelvic infections in a randomized, double-blind, non-inferiority clinical trial. This trial compared ertapenem (1 g intravenously once a day) with piperacillin/tazobactam (3.375 g intravenously every 6 hours) for 3 to 10 days and enrolled 412 patients including 350 patients with obstetric/postpartum infections and 45 patients with septic abortion. The clinical success rates in the clinically evaluable population at 2 to 4 weeks posttherapy (test-of-cure) were 93.9% (153/163) for ertapenem and 91.5% (140/153) for piperacillin/tazobactam.
Ertapenem was evaluated in adults for prophylaxis of surgical site infection following elective colorectal surgery in a multicenter, randomized, double-blind, non-inferiority clinical trial. This trial compared a single intravenous dose of ertapenem (1 g) versus cefotetan (2 g) administered over 30 minutes, 1 hour before elective colorectal surgery. Test-of-prophylaxis was defined as no evidence of surgical site infection, post-operative anastomotic leak, or unexplained antibiotic use in the clinically evaluable population up to and including at the 4-week posttreatment follow-up visit. The trial included 500 patients randomized to ertapenem and 502 patients randomized to cefotetan. The modified intent-to-treat (MITT) population consisted of 451 ertapenem patients and 450 cefotetan patients and included all patients who were randomized, treated, and underwent elective colorectal surgery with adequate bowel preparation. The clinically evaluable population was a subset of the MITT population and consisted of patients who received a complete dose of study therapy no more than two hours prior to surgical incision and no more than six hours before surgical closure. Clinically evaluable patients had sufficient information to determine outcome at the 4-week follow-up assessment and had no confounding factors that interfered with the assessment of that outcome. Examples of confounding factors included prior or concomitant antibiotic violations, the need for a second surgical procedure during the study period, and identification of a distant site infection with concomitant antibiotic administration and no evidence of subsequent wound infection. Three-hundred forty-six (346) patients randomized to ertapenem and 339 patients randomized to cefotetan were clinically evaluable. The prophylactic success rates at 4 weeks posttreatment in the clinically evaluable population were 70.5% (244/346) for ertapenem and 57.2% (194/339) for cefotetan (difference 13.3%, [95% C.I.: 6.1, 20.4], p<0.001). Prophylaxis failure due to surgical site infections occurred in 18.2% (63/346) ertapenem patients and 31.0% (105/339) cefotetan patients. Post-operative anastomotic leak occurred in 2.9% (10/346) ertapenem patients and 4.1% (14/339) cefotetan patients. Unexplained antibiotic use occurred in 8.4% (29/346) ertapenem patients and 7.7% (26/339) cefotetan patients. Though patient numbers were small in some subgroups, in general, clinical response rates by age, gender, and race were consistent with the results found in the clinically evaluable population. In the MITT analysis, the prophylactic success rates at 4 weeks posttreatment were 58.3% (263/451) for ertapenem and 48.9% (220/450) for cefotetan (difference 9.4%, [95% C.I.: 2.9, 15.9], p=0.002). A statistically significant difference favoring ertapenem over cefotetan with respect to the primary endpoint has been observed at a significance level of 5% in this trial. A second adequate and well-controlled trial to confirm these findings has not been conducted; therefore, the clinical superiority of ertapenem over cefotetan has not been demonstrated.
Ertapenem was evaluated in pediatric patients 3 months to 17 years of age in two randomized, multicenter clinical trials.
The first trial enrolled 404 patients and compared ertapenem (15 mg/kg intravenous (IV) every 12 hours in patients 3 months to 12 years of age, and 1 g IV once a day in patients 13 to 17 years of age) to ceftriaxone (50 mg/kg/day IV in two divided doses in patients 3 months to 12 years of age and 50 mg/kg/day IV as a single daily dose in patients 13 to 17 years of age) for the treatment of complicated urinary tract infection (UTI), skin and soft tissue infection (SSTI), or community-acquired pneumonia (CAP). Both regimens allowed the option to switch to oral amoxicillin/clavulanate for a total of up to 14 days of treatment (parenteral and oral). The microbiological success rates in the evaluable per protocol (EPP) analysis in patients treated for UTI were 87.0% (40/46) for ertapenem and 90.0% (18/20) for ceftriaxone. The clinical success rates in the EPP analysis in patients treated for SSTI were 95.5% (64/67) for ertapenem and 100% (26/26) for ceftriaxone, and in patients treated for CAP were 96.1% (74/77) for ertapenem and 96.4% (27/28) for ceftriaxone.
The second trial enrolled 112 patients and compared ertapenem (15 mg/kg IV every 12 hours in patients 3 months to 12 years of age, and 1 g IV once a day in patients 13 to 17 years of age) to ticarcillin/clavulanate (50 mg/kg for patients <60 kg or 3.0 g for patients >60 kg, 4 or 6 times a day) up to 14 days for the treatment of complicated intra-abdominal infections (IAI) and acute pelvic infections (API). In patients treated for IAI (primarily patients with perforated or complicated appendicitis), the clinical success rates were 83.7% (36/43) for ertapenem and 63.6% (7/11) for ticarcillin/clavulanate in the EPP analysis. In patients treated for API (post-operative or spontaneous obstetrical endomyometritis, or septic abortion), the clinical success rates were 100% (23/23) for ertapenem and 100% (4/4) for ticarcillin/clavulanate in the EPP analysis.
NDC 0006-3843-71 in trays of 10 vials.
Do not store lyophilized powder above 25°C (77°F).
The reconstituted solution, immediately diluted in 0.9% Sodium Chloride Injection [see Dosage and Administration (2.7)], may be stored at room temperature (25°C) and used within 6 hours or stored for 24 hours under refrigeration (5°C) and used within 4 hours after removal from refrigeration. Solutions of Invanz should not be frozen.
Patients should be advised that allergic reactions, including serious allergic reactions could occur and that serious reactions may require immediate treatment. Advise patients to report any previous hypersensitivity reactions to Invanz, other beta-lactams or other allergens.
Patients should be counseled to inform their physician if they are taking valproic acid or divalproex sodium. Valproic acid concentrations in the blood may drop below the therapeutic range upon co-administration with Invanz. If treatment with Invanz is necessary and continued, alternative or supplemental anti-convulsant medication to prevent and/or treat seizures may be needed.
Patients should be counseled that antibacterial drugs including Invanz should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Invanz is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Invanz or other antibacterial drugs in the future.
Copyright © 2001-2018 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
sodium, equiv. to 1 gram ertapenem.
Each vial contains 1.046 grams ertapenem sodium, equiv. to 1 gram ertapenem.


text:
Taylor & Kevin
Photography by: Photography by Estefana
San Antonio Weddings » Posts » Taylor & Kevin's Surprise Engagement
Kevin and Taylor met when they worked together at a manufacturing warehouse. Taylor had a boyfriend at the time, and Kevin quit after a month or two. However, Taylor knew there was something about him.
"Probably 6-7 months later I messaged him on Facebook because I couldn't get him out of my head," Taylor said. "A whole bunch of dates and two-ish months later, because I was terrified of him (I knew), I told him 'well we've been walking like ducks & talking like ducks, might as well be ducks."
Two weeks into dating, Taylor told him she loved him and the rest is history.
The proposal was magical and surprised Taylor.
Kevin had one of Taylor's friends convince her that her ring wouldn't be ready for a few months, and not to expect anything soon.
For their anniversary in March, the couple went to Fredericksburg for our anniversary. They were originally supposed to go in February but had to reschedule due to the snowstorm.
"He took me downtown to walk around and have a few wines," Taylor said. "Then, he wanted to go to Cross Mountain because his grandparents used to take him and his brothers there when he was a kid, so I didn't think anything of it."
When they walked to the top, Taylor saw Estefana, their photographer, there which made her suspicious.
"He walked me to the cross at the top and said you're not gonna cry the whole time are you," Taylor said. "I felt myself almost black out. He got down on his knee and said 'you said we've been walking like ducks and talking like ducks right?'"
Taylor said YES!
The ring is from Americus Diamond.
"We went and looked at rings in October," Taylor said. "He went and designed it in January by himself. I had no clue. He said he was stuck in traffic coming home from work."
The Gown
Taylor hasn't chosen on the one for her wedding day just yet, but she plans to get her gown from Liv & Love Bridal.
The couple is set to be married at Paniolo Ranch in Boerne.
"We picked Paniolo Ranch because first off the views are unbelievable," Taylor said. "It just felt right, and it felt like both of our personalities. We also loved the fact that we could do mostly everything ourselves and stay on the property. The owners were super friendly as well and just everything about it felt perfect."
The Vendors
The couple selected their caterer, Perfect Events Boerne.
"She was just so sweet and personable and the food was amazing," Taylor said. "She was a preferred vendor of Paniolo Ranch."
Their chose the same DJ as the one Kevin's brother used at his.
"We had a blast at their reception so that was a no brainer," Taylor said. "My day of coordinator was gifted to me by my lifelong mom away from home, Couture Events by Jill."
Their photographer, Estefana, was found by Kevin for their proposal. They loved her work so much, they decided to keep her for their big day.
Click Below For More Info On Our Featured Vendors
Suggested Blog Posts For You


On this episode of Argot: Audio Short Stories from the Veteran Voices of Pittsburgh Oral History Collection, Korean War veteran Bernie Pular shares a story about receiving the Silver Star medal, as originally told in March 2014 to the Veteran Voices of Pittsburgh Oral History Initiative in Tionesta, Pennsylvania. This audio short story is engineered and produced by Kevin Farkas.
Bernard Pular of Tionesta, Pennsylvania served in the Army during the Korean War. One day on a routine mission he engaged the enemy—Koreans or Chinese—it didn't matter. They were trying to kill him, so he returned the gesture.
That's when "The Pollack"—as his men called him—was cut down by a machine gun. His legs were torn up, but he was able to return fire, saving the mission and his comrades.


To grow and evolve it is important to have insight into yourself. After my 21 year relationship ended in divorce, I struggled with my identity. My ex and I grew up together, it was tough to see who I was solo. When my son started his junior year (Fall 2017), he took this Enneagram test, www.16personalities.com as an assignment, he shared his results with me, then I became curious so I took the test.
I'm a Type 2 Consul (Helper). Consuls enjoy supporting their friends and loved ones, organizing social gatherings and doing their best to make sure everyone is happy.
Embrace and reflect on the knowledge you gain about yourself. The more you know about yourself, the more you understand the "Why's" behind your thoughts and actions. Evolving is a courageous journey! Share below your thoughts and perhaps if you took the test.


"Global efforts to improve access to drinking water have been hampered by rapid urbanisation, with the proportion of people in urban areas with access actually declining, according to U.N. figures presented" at the World Water Week conference in Stockholm, Agence France-Presse reports.
Despite global efforts to increase the numbers of people worldwide who have access to water, "[i]n cities, there are today more people suffering from a poor and unsatisfactory access to safe water and sanitation than at the end of the 20th century," Gerard Payen of the International Federation of Private Water Operators (AquaFed), said in a statement, according to the news service.
Though "hundreds of millions of people" have gained access to water as the result of global efforts, the AFP notes population growth adds to the number of people in need. "Between 2000 and 2008, the world's population increased by 635 million people, 80 percent of whom live in urban areas, according to U.N. numbers," the news service adds.
The article notes "U.N. statistics showing that 114 million more people went without access to tapwater at home or in the immediate vicinity at the end of the eight-year-period. … At the same time, 134 million more people went without access to basic sanitation, the group said, pointing out that in both cases there had been a 20 percent hike of urban dwellers lacking access" (9/7).
"Current efforts to develop access to water and sanitation in cities are outpaced by urbanization," Payen said, according to an AquaFed press release (.pdf). "A surge in the efforts is urgent to reverse this trend. This requires new determination in public policies and practical approaches from operators and system installers of all kind," he said, according to the release (9/7). The AFP highlights the decision by the U.N. General Assembly in July to recognize access to safe drinking water as a human right (9/7).
A report issued on Monday by the U.N. Food and Agricultural Organization (FAO) to coincide with the start of World Water Week examines the potential for recycling urban waste water for crop irrigation to mitigate water scarcity and reduce water pollution, U.N. News Centre reports (9/7).
"The case studies in this report show that safely harnessing wastewater for food production can offer a way to mitigate competition between cities and agriculture for water in regions of growing water scarcity," Pasquale Steduto, deputy director of FAO's Land and Water Division, said in a FAO press release. "In the right settings, it can also help to deal with urban wastewater effluent and downstream pollution," Steduto added.
However, "the FAO said the data indicates that overall the practice is not being as widely implemented as it should," and "calls for the practice to be scaled up," according to the U.N. News Centre (9/7).
The AFP, in a separate story, reports on "the global trend of unpredictable weather patterns and rainfall that threaten food security" – a topic that received attention at the conference, following the impacts of the drought in Russia and floods in Pakistan.
The article examines the impact of unpredictable weather patterns on various regions of the world and includes comments by World Water Week Director Jens Berggren; Colin Chartres, head of IWMI; Jan Lundqvist, who chairs Stockholm International Water Institute's Scientific Programme Committee; and Sunita Narain, the head of the Centre for Science and Environment in India (Larson, 9/7).
In related news, the International Business Times reports that PepsiCo Inc. on Tuesday released a report (.pdf)Â "on the company's efforts to conserve and recycle water and provide increased access to clean water globally" to coincide with World Water Week (9/8). "In April 2010, PepsiCo unveiled a new set of global goals organized around the premise of respecting the human right to water through world-class efficiency in its operations, preserving water resources and enabling access to safe water," according to a PepsiCo press release. The report highlights PepsiCo's progress in several areas (9/7).


text:
Wild Wolf Pups Born in Colorado For First Time in 80 Years
By Travis Smola | June 29, 2021
Colorado has just seen its first wild wolf pup birth in nearly 80 years.
The Colorado Parks and Wildlife Department has confirmed a first in nearly 80 years for the Centennial State. Gray wolf pups. The first to be observed in the wild in almost 80 years. Officials confirmed the presence of at least three pups outside Steamboat Springs back in early June.
The pups are the offspring of two wolves that are well-known to researchers. The female wolf, known as F1084, or simply "Jane" migrated to Colorado from Wyoming where she met up with a male wolf known as "M2101," or John in 2019.
CPW staff confirmed the wild birth June 4 through the 8th while running observations on a den site from two miles away. They are continually monitoring the den to see if there are more pups in the area. The news of the new pups comes hot on the heels of a hotly contested and debated ballot measure passed by voters last November.
In short, the initiative, known as Proposition 114, directs CPW to develop a reintroduction and management plan for gray wolves before 2024 on lands west of the Continental Divide. The initiative provides the use of state funds with assisting livestock owners in potential conflicts. Compensation will be paid to owners of domesticated livestock killed by increasing wolf populations.
In Colorado, wolves remain an endangered species and the fines for shooting one are stiff. Jail time and fines of $100,000 are possible for anyone who kills a gray wolf.
"Colorado is now home to our first wolf litter since the 1940s. We welcome this historic den and the new wolf family to Colorado," Governor Jared Polis said in a press release. "With voter passage last year of the initiative to require re-introduction of the wolf by the end of 2023, these pups will have plenty of potential mates when they grow up to start their own families."
CPW also expressed excitement over the news that wolves have started reproducing in Colorado without human interference. There are no photos of the pups yet, but CPW is hoping to document them soon. CPW said the priority is not disturbing the animals.
"It's incredible that these two adult animals have traveled the distance and overcome the challenges they have to get here, and to now have pups in Colorado," CPW area wildlife manager Kris Middledorf said in the release. "It's our priority to ensure that they have the chance to thrive, so even as we have exciting news, we want to remind everyone that these animals remain endangered in Colorado."
For more outdoor content from Travis Smola, be sure to follow him on Twitter and check out his Geocaching and Outdoors with Travis YouTube channels.
NEXT: THE AXIS DEER AND HOW THEY'RE IMPACTING PARTS OF THE UNITED STATES


The blouse style to wrap up your OOTD with effortless flair.
Ladies, what's new in the world of blouses, you wonder? Well, there are too many of them these days. What's worse is when options are limitless, you are mired by indecision. The cure for this very first world problem? I narrow it down for you, to a style I personally love. Not because I'm certain you'll love it as I do. I don't know if it will appeal but I can't help but to share it anyway!
The wrap blouse is one you might have witnessed and if you're into V-necklines, then this blouse style can quite appeal. With the variety of wrap blouses to pick from, I zoom in on ZALORA's very own chic and sleek design, available in FOUR colors. The ones I'm keen on are the three types you will see. The unique point about the blouse is that it has a half-sleeve cut, a relaxed shape and a self-tie at the waist so you can do the cinch and highlight your womanly curve.
With a wrap-front styling along with the much loved V-neckline, this is a blouse style you can dress up or down with such an ease, it is a crime! I just love the style and would gladly hoard.
Which wrap blouse is your cup of tea? Share below – I'd love to know!


How much are utility parent companies making?
How does this winter heating season compare to the past?
Help Julie and Christie fight rate hikes!
The guy at the door says he's from the utility: Are you sure?


We love reading aloud as a family during the holiday season. I have a pile of "Holiday Books" we get down from the shelf each year. It's always exciting to see them again. Each person in the family has a favorite of their own, but as a whole our family favorites are Arnold Ytreeide's series. These are wonderful stories. As we are learning Bible History and even some current events throughout the year, the children will often say something like, "Oh, that's like in Jotham's Journey!" (click to tweet) I love books that encourage connecting the dots between historical places and events and real life circumstances. If you are looking for a great family tradition to add to your holidays, I strongly suggest getting these books.
Description: In this widely popular, exciting story for the advent season, readers follow ten-year-old Jotham across Israel as he searches for his family. Though he faces thieves, robbers, and kidnappers, Jotham also encounters the wise men, shepherds, and innkeepers until at last he finds his way to the Savior born in Bethlehem.
Description: Bartholomew's Passage is an engaging story that guides families through the Advent season. Young Bartholomew's adventures start when Roman soldiers destroy his village and disperse his family, continue through his enslavement to a tyrannical master and his escape with his new friend Nathan, and end with a reunion with his family in Bethlehem. Along the way Bartholomew makes a new friend, a young boy named Jotham!
Description: Curious, competent, and courageous Tabitha is the daughter of a shepherd who is taking his family on caravan to his birthplace. Along the way, she meets and becomes friends with Jotham and Bartholomew, watches as Romans take her father prisoner, spends time with Zechariah and Elizabeth, helps Mary and Joseph just before Christ's birth, and ends her travels at the stable in Bethlehem.
Description: When Jotham is accused of a terrible crime, his 13-year-old son, Amon, races to save him. Along the way Amon joins the crowds on Palm Sunday, outwits Roman soldiers who plan to kill his father and Jesus, witnesses Judas's betrayal, and beholds Christ's crucifixion. End-of-chapter meditations make this ideal for family Lenten devotions. 208 pages, softcover from Kregel.
See more fun ideas at Paradise Praises What to Read Wednsday Link Up. Come visit to find more holiday reading ideas!
Mary-andering Creatively's Book Musings Mondays Lots of book ideas there!


Jason Groome: 2IP, 0R, H (2B), 30 pitches, 19 strikes, 7 swing/miss (5 on FB, 2 on CB), 3K.
Michael Chavis got promoted to Salem. Unfortunately it doesn't look performance related as he had been 7 for his last 42 with a 0:17 BB:K ratio. It seems like maybe he got promoted to prevent him from getting too psychologically down and maybe as a precursor to Dalbec getting promoted.
Tyler Hill's been hitting rather well in Lowell (.347/.414/.515 in 52 games). Bobby Dalbec's also hitting .386/.426/.727 in 23 games in Lowell.
Kopech's rocking a 14.2 K/9 in Salem right now. That figure would rank among the best relievers in MLB, never mind starting pitchers. He's struck out 10 or more batters in three consecutive starts and in four of his last five starts. The walk rate is still kinda high (4.2), but he's walked only 9 batters in 29 innings this month (as opposed to 15 in 22.1 innings in July).
Jason Groome being promoted to Lowell. Bradford said he will start either Thursday or Friday in Connecticut.
Kind of surprised Groome got promoted so soon after all of just 4 innings in the GCL. They held to their word when they signed him that he'd be pitching in Lowell after some time down in Florida. The longer it went before he made an appearance had me thinking that promoting him to Lowell would be unlikely but here it is. It's a pretty unusually aggressive move. Sure Logan Allen and Enmanuel DeJesus pitched a few innings in Lowell last year but they had gotten in a lot more appearances in the GCL. High school pitchers almost always spend the entire season down in the GCL after getting drafted or get promoted to a lower level short-season season than the New York Penn League.
Obviously very excited about Kopech. There have been big improvements with his delivery and slider. Kopech and Groome are as talented a pair of pitching prospects as there is in baseball. There are almost zero promising pitching prospects at the Double-A and Triple-A levels but the pitching propects at the lower minors is looking better, even after Kopech and Groome. I really like Raudes and if his velocity takes a leap next season, he'll be extremely intriguing. I really liked the Shawaryn selection too. Josh Pennington has a huge arm and has pitched really well his last three times out at Lowell.
Victor Diaz has become a very intriguing reliever or re-intriguing reliever if that's allowed in the english language. He came into the season as a member of an ever expanding list of pitchers who've hit 100 mph and since the Red Sox farm system isn't stocked with many hard throwing relievers, that made him very notable. Unfortunately he absolutely bombed early in the year. The opposition would have trouble scoring up to the point he entered and then they'd score like 5 runs in his outings. I thought for sure he'd be demoted to extended spring training and then later show up at Lowell. It wouldn't have been the end of the world because he had been pushed aggressively from the DSL, him being 22 I assume being one of the reasons. Instead he stayed and has pitched so well that he's become Greenville's closer.
More than stats, whether good or bad, I really like how smooth his motion is. On paper, if you see that a pitcher hits 100 mph, is a bit older than usual for his lack of experience and is a reliever, it wouldn't be a bad guess to assume that he's stiff in some ways and/or his delivery is violent. That is not the case with Diaz. He has the big fastball and a slider that looks good to me but just as importantly, I think he has the delivery and coordination to throw enough good strikes to be a potential major leaguer.
Can't wait to see how he does in 2017. Here's hoping he'll pull a Mookie and continue hitting for some power. Either way, he could become a nice trade chip.


M/Y Galactica Star, a 213-foot (65m) Heesen launched in 2013, is for sale in a judicial 45-day sealed bid through Fraser that began April 4 and will close May 19.
The aluminum yacht's fast displacement hull and two MTU 20V 4000 M93L engines have a 4,200nm cruising range at 14 knots, and a top speed of about 28 knots, according to a Fraser press release. The yacht is fitted with Zero Speed stabilization, is built to ABS classification and LY2, and an ABS five‐year survey was recently completed.
There are six staterooms to accommodate 12 guests, and six cabins for 12 crew, plus the captain's cabin. The interior was designed by Bonnenberg and Rowell, while the exterior was designed by Omega Architects.
For more information, contact Fraser broker Josh Gulbranson or visit yachtgalacticastarsale.com.